Faecal Microbiota Transplantation

FMT is portrayed as especially effective for Clostridium difficile infection. Capsule delivery is presented as less invasive and potentially more acceptable for paediatric participants than procedural delivery routes. FMT is described as a direct method for introducing another person's gut microbes. TURN2 uses four weekly FMT administrations during weeks 0–3. The selected FMT regimen reflects a feasibility compromise because there is no consensus dose for non-infectious indications. The original TURN trial did not find a statistically significant remission difference between fresh nasoduodenal donor FMT and autologous FMT. Prior randomized trials of FMT for active ulcerative colitis reported treatment effects of 24–32% compared with placebo rates of 5–9%. Donor quality is considered critical because the transplant depends on the donor's microbial profile. One-time FMT is portrayed as unrealistic for chronic autoimmune or inflammatory conditions. Germ-free mouse studies are used to support the transmissibility of obesity-like traits through stool microbiota. A case report is used to suggest that metabolic traits may transfer after FMT, though it is not definitive. Faecal microbiota…